Related Articles
Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patients
A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients
Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients who failed two or more treatment regimens
Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis
Personalized peptide vaccination in patients with refractory non-small cell lung cancer